+211.0%
PDD vs GSK
+82.3%
+128.7%
-87.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.1% | -0.2% | -0.9% | -1.0% |
| 7D | +5.6% | +1.7% | +4.0% | +5.0% |
| 30D | +5.8% | +7.0% | -1.3% | +3.4% |
| 3M | -8.6% | -2.7% | -6.0% | -8.0% |
| 6M | -18.8% | +1.4% | -20.3% | -19.7% |
| YTD | -26.8% | +5.3% | -32.1% | -28.8% |
| 1Y | -39.3% | +10.6% | -49.9% | -41.9% |
| 3Y | -22.5% | +62.6% | -85.1% | -37.6% |
| 5Y | -0.8% | +41.7% | -42.4% | -16.1% |
| All | +211.0% | +82.3% | +128.7% | +146.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling